Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on April 20, 2026 reporting Item 8.01 (Other Events). Phase 3 STAR-121 discontinued for futility in first-line metastatic NSCLC.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 3 STAR-121 discontinued for futility in first-line metastatic NSCLC
- Domvanalimab combination failed pre-planned futility analysis versus pembrolizumab plus chemotherapy
- Exploratory zimberelimab combination showed consistent overall survival versus pembrolizumab combination
- Gilead ending option continuation payment; rights to additional programs expire July 14, 2026
- Arcus retains full casdatifan rights except territories licensed to Taiho; EDGE-Lung also discontinued
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.